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Purpose: Seizures are a common manifestation of many diseases and play an important role in the
clinical presentation and quality of life (QOL) in patients with gliomas. The purpose of the present study
was to investigate the possible correlation between tumor-related seizures and clinicopathological
factors that inﬂuence preoperative seizure characteristics and relevant survival outcomes.
Methods: We retrospectively investigated the correlation of preoperative seizures with clinicopatho-
logical factors and prognosis in a cohort of 198 Chinese patients with anaplastic gliomas. Univariate and
multivariate logistic regression analyses were used to identify factors associated with preoperative
seizures. Survival function curves were calculated using the Kaplan–Meier method.
Results: Of the 198 patients, 68 (34.3%) patients had preoperative seizures. Among the patients with
seizures, 26 (38.2%) had generalized seizures, 38 (55.9%) had simple partial seizures, and four (5.9%)
complex seizures. There was a higher proportion of epidermal growth factor receptor (EGFR)
ampliﬁcation, frontal lobe involvement, left cerebral hemisphere involvement, and lower Ki-67
expression in patients with preoperative seizures in both univariate and multivariate analyses. Patients
with preoperative seizures had a longer overall survival (OS) time compared with those without
(median: 1924 days vs. 923 days, P = 0.048).
Conclusion: The current study updates existing information on tumor-related seizures and clinico-
pathological factors in anaplastic gliomas, and suggests two putative biomarkers for preoperative
seizures; Ki-67 expression and EGFR ampliﬁcation. These factors may provide insights for developing
effective treatment strategies aimed at prolonging patient survival.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The World Health Organization (WHO) classiﬁes gliomas into
four grades, of which anaplastic astrocytoma, oligodendroglioma,
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights retumors.1 In the United States, glioblastomas account for approxi-
mately 6070% of malignant gliomas, anaplastic astrocytomas for
1015%, and anaplastic oligodendrogliomas and anaplastic
oligoastrocytomas, 10%.1,2 In China, the percentage of anaplastic
gliomas is much higher.3 Prognosis of anaplastic gliomas is
inﬂuenced by age, symptom duration, mental health status, and
Karnofsky performance status.4 Based on a large database of
clinical trials, the Radiation Therapy Oncology Group (RTOG)
deﬁned six prognostic classes. Classes I–III describe anaplastic
astrocytoma, while classes IV–VI deﬁne glioblastomas.5,6 A
previous analysis illustrated the diversity in outcome of patients
diagnosed with anaplastic gliomas.4served.
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with gliomas.7–10 When uncontrolled, tumor-related epilepsy has
a signiﬁcant impact on patients’ QOL, causes cognitive deteriora-
tion, and may result in signiﬁcant morbidity.11–14 The persistence
of seizures and the use of anti-epileptic drugs (AEDs) may
negatively inﬂuence QOL and cognitive function.11,13 More than
one third of patients with anaplastic gliomas experience epileptic
seizures at disease onset,15–19 and not all anaplastic gliomas are
associated with seizures, despite having similar histology and
tumor location. It is likely that variability in the presence of
seizures cannot be explained entirely by tumor-related factors, but
instead may be a complex interaction between tumor-related and
genetic factors. Although, to date, some susceptibility candidate
genes associated with tumor-related seizures have been identiﬁed
in low-grade gliomas,20,21 few studies have focused on anaplastic
gliomas.
To investigate molecular genetic proﬁles that might correlate
with the presence of seizures, and the possible correlation between
tumor-related seizures and survival outcome in Chinese patients
with anaplastic gliomas, we retrospectively analyzed a series of
198 gliomas, including 39 anaplastic oligodendrogliomas, 103
anaplastic oligoastrocytomas, and 56 anaplastic astrocytomas, for




We retrospectively identiﬁed all patients (>18 years old) with
anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO),
anaplastic oligoastrocytoma (AOA) from the Chinese Glioma
Genome Atlas (CGGA), who underwent surgical resection at the
Glioma Treatment Center of Beijing Tiantan Hospital from January
2006 to July 2012. Histological diagnosis was reafﬁrmed by two
independent neuropathologists and graded according to the WHO
classiﬁcation.1 Cases with discrepancies were re-reviewed by
another pathologist until a consensus was reached. Clinical data,
including patient’s age at diagnosis, sex, presenting symptoms,
preoperative Karnofsky performance status (KPS) score, and
operation status, were obtained from medical records. OS time,
deﬁned as the period from surgery to death, was collected when
patients visited the clinics and in phone interviews with patients
and/or their relatives. Progression-free survival (PFS) was deﬁned
as the time of surgery until radiographic progression (the
appearance of a new lesion or an increase in tumor size of
25%). Patients who were lost to follow-up or who died of non-
primary diseases were excluded. This study was approved by the
Ethics Committee of Beijing Tiantan Hospital, and written
informed consent was obtained from all patients.
2.2. Preoperative seizure characteristics
Data on seizure characteristics included date of seizure onset
and type of seizure (simple partial, complex partial, and general-
ized seizures). The study population was divided into two groups
based on preoperative seizure status.
2.3. Tumor location
Tumor location was considered to be the lobe or region of the
brain within which the bulk of the glioma resided. These
assignments were based on an evaluation of medical records
and imaging study results, mainly MRI characteristics including
tumor side (left, right, or bilateral) and speciﬁc lobe involvement
(frontal, temporal, parietal, occipital, and insula).2.4. Samples
Tumor tissue samples were obtained by surgical resection
before treatment with radiation and/or chemotherapy. Resected
specimens were snap-frozen and stored in liquid nitrogen until
DNA extraction or parafﬁn-embedding.
2.5. DNA extraction
Genomic DNA was isolated from frozen tumor tissues using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. DNA concentration and quality were
measured using a NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies, Houston, TX, USA).
2.6. Molecular evaluations
All data from the CGGA for which biomaterial was available,
IDH mutation status (pyro-sequencing for IDH1/2 mutation),
MGMT promoter methylation (DNA pyro-sequencing), and Ki-67
expression level (immunohistochemistry) were assessed accord-
ing to routine methods.22,23
2.7. Detection of 1p/19q deletion by ﬂuorescence in situ
hybridization (FISH)
The 1p/19q ﬂuorescent probe kit (Vysis Inc., Downers Grove, IL,
USA) was used for FISH. Brieﬂy, 4-mm-thick parafﬁn slides were
deparafﬁnized, dehydrated, and incubated in 1 mol/L NaSCN for
35 min at 80 8C. Slides were then immersed in pepsin solution
(0.65% in protease buffer with 0.01 mol/L HCl) for 10 min at 37 8C,
and tissues were ﬁxed with 10% neutral buffered formalin. Then,
the specimens were dehydrated in an ethanol series (70%, 85%, and
100%, 2 min in each bath) and air-dried, 20 ml of each probe was
added separately, and slides were sealed with rubber cement. After
co-denaturation for 10 min at 75 8C, the slides were then placed in
a humidiﬁed atmosphere with Hybrite (ThermoBrite, Vysis) for
16 h at 37 8C. Slides were immersed ﬁrst in 2 SSC/0.3% NP-40 for
2 min at RT (room temperature) and then in 2 SSC/0.3% NP-40 for
2 min at 73 8C. After drying, nuclei were counterstained with
4,6-diamidino-2-phenylindole (DAPI) and anti-fade compound
(p-phenylenediamine). FISH signals for each locus-speciﬁc FISH
probe were assessed under an Olympus BX51TRF microscope
(Olympus, Ina-shi, Nagano, Japan) equipped with a triple-pass
ﬁlter (DAPI/Green/Orange; Vysis). The assessment and interpreta-
tion of FISH results were made according to guidelines deﬁned by
the SIOP Europe Neuroblastoma Pathology and Biology and Bone
Marrow Group.24 For each probe, more than 100 non-overlapping
nuclei were enumerated per hybridization. Tumors with more than
30% of nuclei showing DNA loss were deﬁned as tumors with
chromosomal loss.
2.8. Analysis of EGFR ampliﬁcation by ﬂuorescence in situ
hybridization (FISH)
A probe for the EGFR locus (7p11.2), labeled with Texas Red,
was used in combination with a ﬂuorescein isothiocyanate-
labeled centromeric probe for chromosome 7. The procedure was
performed according to the manufacturer’s instructions (Cyto-
cell, Cambridge, UK). The tissue section was incubated at 56 8C
overnight, deparafﬁnized in xylene, hydrated in 100% and 70%
ethanol, and treated with 0.1 M HCl at RT for 20 min. After
incubation in the pretreatment reagent (Abbott Molecular Inc.,
Des Plaines, IL, USA) at 80 8C for 30 min, the section was
digested with pepsin (2 mg/mL in 0.01 M HCl) at 37 8C for
1020 min and dehydrated in an ethanol series. The probe set
P. Yang et al. / Seizure 23 (2014) 844–851846was applied, and the section was covered with a coverslip and
sealed with rubber cement. For denaturation, the slides were
incubated at 75 8C for 5 min; for hybridization, they were placed
in a humidiﬁed chamber at 37 8C overnight. Post-hybridization
washes were performed in 0.4 saline sodium citrate buffer
(0.4 SSC)/Nonidet P-40 (NP-40; pH 7.0) at 72 8C for 2 min and in
2 SSC/NP-40 (pH 7.0) at RT for 1 min. After washing and drying
at RT, the slide was counterstained with 40-6-diamidino-2-
phenylindole I (10 ng/mL; Abbott Molecular Inc.) and analyzed
via FISH. FISH results were represented as the ratio of EGFR to
chromosome 7 centromeric signals from 50 non-overlapping
tumor cell nuclei. Gene ampliﬁcation was deﬁned as the
presence of EGFR gene clusters and 2.0 or 15 copies of EGFR
per cell in 10% of the total cells.
2.9. Follow-up
Survival data were collected by clinics during patient visits and/
or in phone interviews. Patients who underwent biopsy only were
not followed up at our center, and were therefore excluded from
the survival analysis.
2.10. Statistical analysis
All statistical analyses were performed using SPSS version 13.0
(SPSS, Chicago, IL, USA) and were tailored to address associations
between the presence of preoperative seizures and clinicopatho-
logical characteristics and survival outcomes. Survival function
curves were calculated using the Kaplan–Meier method, and
differences were evaluated using the log-rank test. Univariate
analyses were carried out using the chi-square test for dichoto-
mous variables and the Mann–Whitney U-test for continuous
nonparametric data. All variables associated with preoperative
seizures in univariate analysis (P < 0.05) were then included in a
backward stepwise multivariate logistic regression model. A
probability value of 0.05 was considered statistically signiﬁcant
after two-sided P-values were computed.
3. Results
3.1. Patient clinicopathological characteristics
We searched the database of the CGGA to ﬁnd patients who had
undergone primary resection of cerebral anaplastic gliomas
between January 2006 and July 2012. This study group comprised
198 patients (114 males and 84 females; age range, 18–74 years;
median age, 43 years) who were >18 years of age and who had
WHO grade III disease. The breakdown of patients was as follows:
56 with AA, 39 with AO, and 103 with AOA diagnosed by
histopathology. We excluded patients who had undergone
secondary resection or needle biopsy only and those with
infratentorial anaplastic gliomas. The main clinical characteristics
of the 198 patients are summarized in Table 1.
The pretreatment KPS scores ranged from 30 to 100 (median,
80). Tumor location was analyzed using MRI characteristics; 90
tumors were located in the left cerebral hemisphere, 85 in the right
side, and 15 bilaterally. The most commonly involved lobe was the
frontal (n = 114, 57.6%), followed by the temporal (n = 80, 40.4%),
the parietal (n = 29, 14.6%), the insula (n = 23, 11.6%), and the
occipital (n = 20, 10.1%).
All of the patients were successfully analyzed for LOH 1p, LOH
19q, 1p/19q codeletion, and EGFR ampliﬁcation. We also collected
available data on IDH1 mutation (n = 161), IDH2 mutation
(n = 140), MGMT promoter methylation (n = 32), TP 53 mutation
(n = 104), PTEN mutation (n = 100), and IHC-based Ki-67 protein
expression levels (n = 177).3.2. Seizure semiology
The seizure types of the 198 patients with anaplastic gliomas
are listed in Table 1. Of the 198 patients, 68 (34.3%) patients had
preoperative seizures, and 130 (65.7%) had no preoperative
seizures. Of the 68 patients with seizures, 26 (38.2%) patients
had generalized seizures, 38 (55.9%) had simple partial seizures,
and four (5.9%) had complex seizures.
To identify factors that might be associated with preoperative
seizures, demographic and tumor information was compared
between patients with seizures and those without (see Table 1 for a
complete list). In the univariate analysis, only ﬁve variables were
signiﬁcantly associated with the presence of seizures: frontal lobe
involvement (frontal lobe involved vs. not involved, P = 0.01, chi-
square test), occipital lobe involvement (occipital lobe involved vs.
not involved, P = 0.08), tumor in the left cerebral hemisphere (left
vs. right and bilateral, P = 0.036), EGFR ampliﬁcation (ampliﬁed vs.
not ampliﬁed, P = 0.025), and Ki-67 expression level (high
expression vs. low expression, P = 0.027). Representative immu-
nohistochemical staining for Ki-67 using a scale of 0–3 (0 = low,
3 = high expression) and FISH analysis of EGFR ampliﬁcation with
negative and positive results are shown in Figs. 2 and 3,
respectively. No other clinical or pathological variables were
found to be associated with an increased risk for preoperative
seizures in this group of patients. In the multivariate analysis, four
of the ﬁve factors were found to have a strong association with
preoperative seizures: frontal lobe involvement, left side involve-
ment, low Ki-67 expression level and EGFR ampliﬁcation were
independent factors for a higher incidence of preoperative seizures
(P-values, odds ratios, and 95% conﬁdence intervals are shown in
Table 2).
3.3. The prognostic value of preoperative seizures in anaplastic
gliomas
Of the 198 anaplastic glioma patients, the median OS and PFS
were 1314 days and 764 days, respectively. Patients with
preoperative seizures had a longer OS compared to those without
seizures (median: 1924 days vs. 923 days, P = 0.048, Table 3 and
Fig. 1a). For PFS, patients with preoperative seizures also showed
better prognosis, but without statistical signiﬁcance (median: 947
days vs. 548 days, P = 0.155, Table 3 and Fig. 1b).
4. Discussion
Seizures play an important role in patients’ postoperative
QOL,25 especially patients with low-grade gliomas (LGGs) and
anaplastic gliomas, because of the duration of their survival. At
present, there are two hypotheses by which the pathogenesis of
tumor-related seizures can be explained. The ﬁrst hypothesis
involves the mechanical compression of the normal tissue
surrounding the tumor because of mass effect, resulting in the
affected tissue becoming an epileptic focus following ischemia and
hypoxia. The basis of the other hypothesis is that the tumor itself
excretes chemical factors that change the peritumoral microenvi-
ronment into an epileptic focus. Chang et al.7 observed that the
extent of tumor resection might be an independent factor
predicting epileptic prognosis. A few researchers have explored
the second hypothesis. Bordey and Sontheimer26,27 reported that
astrocytic tumor cells might generate action potentials, which
might themselves be the source and propagation route of epileptic
activity. Other studies28,29 demonstrated that glioma cells released
glutamate and killed peritumoral neurons by an excitotoxic
mechanism. These ﬁndings revealed an important role of gluta-
mate in the genesis of glioma-related seizures. Each of the two
explanations is possible. Our previous studies20,21,30 on LGGs also
Table 1
Clinical and molecular characters of 198 patients.
Variable Total Seizures P value
Yes No
No. of patients 198 68 130
No. of sex
Male 114 37 77 0.547
Female 84 31 53
Median age in years (range) 43 (14–74) 42 (18–65) 43 (14–74)
Age <40 years old
<40 years old 77 28 49 0.648
340 years old 121 40 81
Tumor location (involvement)
Frontal 114 48 66 0.01
Temporal 80 24 56 0.36
Parietal 29 10 19 0.99
Occipital 20 3 17 0.08
Insula 23 8 15 0.99
Tumor side
Left 90 38 52 0.036
Right 85 24 61 0.132
Bilateral 15 5 10 0.99
Tumor pathology
AA 56 19 37 0.99
AO 39 14 25 0.852
AOA 103 35 68 0.99
Seizure type
Secondary generalized 26 26 NA
Simple partial 38 38 NA
Complex partial 4 4 NA
Ki-67
High expression 74 20 54 0.027
Low expression 103 45 58
PTEN mutation
Mutation 8 4 4 0.434
Wildtype 92 29 63
IDH1 mutation
Mutation 90 33 57 0.742
Wildtype 71 24 47
IDH2 mutation
Mutation 2 0 2 0.53
Wildtype 138 52 86
MGMT methylation
High methylation 18 6 12 0.72
Low methylation 14 6 8
TP53 mutation
Mutation 23 8 15 0.99
Wildtype 81 28 53
1p deletion
Deletion 37 14 23 0.702
No deletion 161 54 107
19q deletion
Deletion 38 13 25 0.99
No deletion 160 55 105
1p/19q codeletion
Deletion 30 11 19 0.835
No deletion 168 57 111
EGFR ampliﬁcation
Ampliﬁcation 16 10 6 0.025
No ampliﬁcation 182 58 124
AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma.
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miR-196b were associated with the occurrence of preoperative
seizures.
Based on the assumption that the biological behavior of
gliomas may to some extent be related to the presence of
seizures, we retrospectively analyzed a data-set from 198
Chinese patients who were diagnosed with cerebral hemispheric
anaplastic gliomas. We aimed to identify the clinicopathological
factors associated with preoperative seizures and the differences
in survival outcome between patients with and without
preoperative seizures. This large cohort of anaplastic glioma
patients was treated at a single institute in China over a period of
6 years.The percentage of patients presenting with seizures (34.3%) is
consistent with that (35–45%) reported in previously published
studies concerning anaplastic gliomas.31–33 Some prior studies
have also indicated that oligodendroglial tumors, including
oligodendrogliomas and oligoastrocytomas, are more frequently
associated with seizures than with astrocytomas.33 However, our
data did not show any signiﬁcant difference in seizure incidence
associated with the three different tumor types. This may be due to
differences in the histological diagnostic criteria used in different
hospitals. Different authors have suggested various histological
cut-off values for the oligodendroglial component to separate
oligoastrocytomas from astrocytomas. In our center, an oligoas-
trocytoma was pathologically diagnosed only if the proportion of
Fig. 1. Kaplan-Meier estimates of overall survival (A) and progression-free survival (B) according to seizure occurence.
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different planes. Otherwise, it was considered to be a ‘‘pure’’
astrocytoma.21 In this study, we conﬁrmed a previous ﬁnding by
Chang et al. 7 that seizure occurrence is closely related to the
location of tumors. Gliomas with frontal involvement tend to be
associated with a higher incidence of preoperative seizures.
Speciﬁcally, we demonstrated that patients with tumors locatedFig. 2. Photomicrographs of tumor tissue stained for Ki67 with different scores. (A) Low K
(score 2). (D) High Ki67 expression (score 3). Original magniﬁcation: x400.in the left cerebral hemisphere were more likely to present with
seizures. This could be explained by the fact that our patients were
mainly right-handed with a left-side dominant hemisphere, which
means the functional location is mainly in the left hemisphere
(e.g. Broca’s area). An observational retrospective multicenter
study conducted in 1509 patients with diffuse LGGs demonstrated
the result that tumor anatomical and functional locations werei67 expression (score 0). (B) Low Ki67 expression (score 1). (C) High Ki67 expression
Fig. 3. FISH analysis of EGFR ampliﬁcation with negative (A) and positive (B) results.
Table 2
Multivariate predictors of preoperative seizures.
Variable Odds ratio 95% CI P value
Frontal involvement 0.43 0.22–0.86 0.019
Occipital involvement 0.96 0.39–2.38 0.94
Left side involvement 0.41 0.21–0.79 0.008
Ki-67 expression level 2.13 1.07–4.26 0.03
EGFR ampliﬁcation 0.24 0.08–0.77 0.017
P. Yang et al. / Seizure 23 (2014) 844–851 849predictive of epileptic seizure incidence.34 Lesions with left
cerebral hemisphere involvement might be related with higher
incidence of seizures because it is these functional cortical areas
through which the epileptic activities manifest clinical symptoms
during seizure.
Of the 68 patients who presented with preoperative seizures,
we identiﬁed two important molecular pathological character-
istics; low Ki-67 expression and positive EGFR ampliﬁcation. Based
on the second hypothesis concerning the pathogenesis of tumor-
related seizures outlined previously, these molecular genetic
effects may alter the balance between intracortical inhibitory and
excitatory mechanisms, therefore inducing epileptogenic activity.
Tumor-correlated biomarkers have been a popular research topic
during the past 20 years. Several studies on the pathogenesis of
both idiopathic and symptomatic epilepsy have identiﬁed a
number of seizure-related candidate genes.35–37 Previously, we
have shown a relationship between Ki-67 expression and seizure
prognosis.20,21 In this study, we further conﬁrmed that Ki-67 might
inﬂuence preoperative seizures in anaplastic gliomas. Prayson
found that proliferating cells appeared to be primarily astrocytic
and endothelial in nature, and suggested that malformation of
cortical development lesions may not be static.38 Kee et al.
provided evidence implicating Ki-67 as a marker of proliferation in
the initial phase of adult neurogenesis.39 Our results are consistent
with these ﬁndings. Rush found that 86% of Ki-67-positive cells
also expressed protein patched homolog 1 (a component of the
Hedgehog pathway), and showed a signiﬁcant correlation between
the expression of the Hedgehog pathway and Ki-67 in 20 pilocytic
astrocytomas. These results indicate that Ki-67 may, to some
extent, play a role in seizure-related tumors by increasing
proliferation. Furthermore, lower Ki-67 expression is usually
associated with more benign tumors, which may also be relatedTable 3
Survival of patients.
Overall survival P va
Median 95% CI 
All 1314 820–1807 
Seizure 1924 1038–2809 0.04
No. seizure 923 369–1476 to increased incidence of preoperative seizures. In addition, we
speculate that Ki-67 may become a novel diagnostic or therapeutic
target for tumor-related seizures in the future.
EGFR is a tyrosine kinase that binds to extracellular EGF and
dimerizes, thus mediating signal transduction across the cell
membrane. This signal elicits a downstream cascade through the
mitogen-activated protein kinase/extracellular signal-regulated
kinase and phosphatidylinositol 3-kinase/Akt pathways that are
generally favorable to growth and cell migration.40 Although such
signaling is critical for normal organism development, glioma cells
frequently use EGFR signaling to promote tumor behavior. Gliomas
employ several methods to up-regulate EGFR signaling including
overexpression of the receptor via disrupted regulatory feed-back,
thereby sensitizing the cell to extracellular EGF; overexpression via
EGFR gene ampliﬁcation on 7p12; and a truncation mutation,
producing a constitutively active EGFRvIII.41 Furthermore, the
likelihood of EGFR ampliﬁcation increases with WHO glioma grade
and is most common in GBM.42 In this study, EGFR ampliﬁcation
was shown to be an independent predictor for preoperative
seizures in patients with anaplastic gliomas, a ﬁnding that has not
been previously reported. There may be two reasons to explain this
result. First, anaplastic gliomas may mask an adverse impact of
EGFR in their grade II oligodendrogliomas.40 Our data of 198
patients with grade III tumors showed a slight association between
longer survival and EGFR ampliﬁcation, although this association
did not reach the level of statistical signiﬁcance. However, this
ﬁnding has precedence in the literature, with two previous reports
that EGFR expression is closely correlated with EGFR ampliﬁcation
and is related to longer survival in grade III anaplastic oligden-
droglial tumors; this is the exact opposite of what was seen in their
grade II counterparts.40,43 It should be noted that this may be
difﬁcult to explain from a biological perspective, considering the
pro-oncogenic effects of EGFR but this might explain the
correlation of EGFR ampliﬁcation and increased incidence of
preoperative seizures in grade III gliomas. The second explanation
is that the effect of EGFR ampliﬁcation in gliomas depends greatly
on tumor grade, thus, raising the question of whether there are any
differences in expression proﬁles between different grades that
might account for this. For example, Akt activation can trigger
matrix metalloproteinase expression via a p300-dependent
mechanism,44 yet p300 expression is lower in grade III versus
grade II gliomas.45 Alternatively, excessive oncogene signaling canlue Median progression-free survival P value
Median 95% CI
746 431–1060
8 947 361–1532 0.155
548 120–975
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antiproliferative mechanisms, such as cell senescence.46 It can be
speculated that many grade III gliomas, already having achieved
robust proliferation and invasiveness, cannot respond to additional
EGFR in the same way as a less aggressive tumor. This might also
account for the high incidence of preoperative seizure in anaplastic
gliomas with EGFR ampliﬁcation.
We observed a signiﬁcant relationship between outcome and
preoperative seizures. Patients with preoperative seizures have
much better survival outcomes for both OS and PFS. We propose
two hypotheses regarding the better survival outcome of patients
with preoperative seizures. The ﬁrst is based on biological behavior
and etiopathology. Patients with LGGs are associated with better
survival outcomes, with 65–90% of patients experiencing symp-
tomatic seizures.7,47,48 WHO grade III tumors with preoperative
seizures may be similar to LGGs (WHO grade II) with more benign
biological behavior and comparatively better survival. The other
hypothesis is based on tumor location. Lesions with greater cortical
involvement tend to be associated with a higher incidence of
preoperative seizures, as shown in our previous study.21 Tumors
with cortical involvement are always more likely to be totally
resected, and patients with total tumor resection tend to have
better survival.
In contrast to previous studies,7 however, we did not ﬁnd that
patients with IDH mutation status, 1p/19q deletion, tumors of the
temporal lobe, and tumors with oligodendroglial component
subtypes were signiﬁcantly more likely to present with seizures.
These negative ﬁndings could be due to several reasons such as
differences in study design and the different populations studied.
Future research should focus on identifying susceptibility candi-
date genes for tumor-related seizures in larger multicenter studies,
including low- and high-grade gliomas with and without
symptomatic seizures.
This is the ﬁrst study involving a large number of Chinese
patients with anaplastic gliomas from a single center conducted to
identify clinicopathological susceptibility factors for tumor-relat-
ed seizures, and survival differences between patients with and
without preoperative seizures. Our ﬁndings offer useful insights
into the pathogenesis of preoperative seizures in anaplastic
gliomas. Speciﬁcally, Ki-67 expression and EGFR ampliﬁcation
correlated with preoperative seizures, and are potential patholog-
ical biomarkers. Our results may provide useful information for the
current management of patients with anaplastic gliomas suffering
from symptomatic seizures. However, prospective studies are
needed to provide better evidence to guide clinical decision
making.
In summary, epilepsy is one of the major issues facing patients
with anaplastic gliomas. It signiﬁcantly impacts on patients’ QOL.
Frontal involvement, left cerebral hemisphere involvement, and
EGFR ampliﬁcation, as well as low-level Ki67 expression, predis-
posed patients to a favorable outcome in terms of preoperative
seizures in the current study. Thus, these factors may provide
insights into developing effective treatment strategies aimed at
prolonging patient survival.
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